The History of Product Label Changes for DEFINITY® in the US

Harshal R. Patil, M. Main
{"title":"The History of Product Label Changes for DEFINITY® in the US","authors":"Harshal R. Patil, M. Main","doi":"10.15420/USC.2012.9.1.35","DOIUrl":null,"url":null,"abstract":"a previously unmet clinical need: at least 10–15 % of echocardiograms in the US are ‘technically difficult,’ usually because of patient-related factors, including lung disease and obesity. 21 Such examinations are usually salvaged with the administration of a UCA. This prevents downstream testing, lowers healthcare costs, and results in more timely and accurate diagnoses. 22 DEFINITY was contraindicated at product approval in two patient subsets: those with known hypersensitivity to octafluoropropane (perflutren, the constituent gas within the DEFINITY microbubble), and those with known cardiac shunts. Additionally, product labeling specifically contraindicated intra-arterial injection and use in patients with prior hypersensitivity reactions to perflutren. The contraindication in patients with shunts and the prohibition of intra-arterial injection are related to a theoretical concern regarding the potential for systemic embolization. Although the diameter of a DEFINITY microbubble ranges from 1.1 μ m to 3.3 μ m, about 2 % of these microbubbles are >10 μ m, with a maximum diameter of 20 μ m. 1 Although, under normal conditions, this small subset of microbubbles >10 μ m are filtered by the pulmonary microvasculature, larger microbubbles could access the systemic circulation in patients with intracardiac shunts (or following direct intra-arterial injection) and Abstract DEFINITY ® (Perflutren Lipid Microsphere Injectable Suspension, Lantheus Medical Imaging, North Billerica, MA) was approved by the US Food and Drug Administration in 2001 for “opacification of the left ventricular border in patients with technically difficult echocardiograms”. Since then, product labeling has been substantially revised on three occasions, initially due to safety concerns, and more recently to reflect a large body of literature which supports the excellent risk–benefit profile of this agent. This article describes in detail the substantive modifications of the product labeling for DEFINITY since 2001, and the associated supportive scientific data and public regulatory meetings.","PeriodicalId":74859,"journal":{"name":"Spring simulation conference (SpringSim)","volume":"28 1","pages":"35-39"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Spring simulation conference (SpringSim)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/USC.2012.9.1.35","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

a previously unmet clinical need: at least 10–15 % of echocardiograms in the US are ‘technically difficult,’ usually because of patient-related factors, including lung disease and obesity. 21 Such examinations are usually salvaged with the administration of a UCA. This prevents downstream testing, lowers healthcare costs, and results in more timely and accurate diagnoses. 22 DEFINITY was contraindicated at product approval in two patient subsets: those with known hypersensitivity to octafluoropropane (perflutren, the constituent gas within the DEFINITY microbubble), and those with known cardiac shunts. Additionally, product labeling specifically contraindicated intra-arterial injection and use in patients with prior hypersensitivity reactions to perflutren. The contraindication in patients with shunts and the prohibition of intra-arterial injection are related to a theoretical concern regarding the potential for systemic embolization. Although the diameter of a DEFINITY microbubble ranges from 1.1 μ m to 3.3 μ m, about 2 % of these microbubbles are >10 μ m, with a maximum diameter of 20 μ m. 1 Although, under normal conditions, this small subset of microbubbles >10 μ m are filtered by the pulmonary microvasculature, larger microbubbles could access the systemic circulation in patients with intracardiac shunts (or following direct intra-arterial injection) and Abstract DEFINITY ® (Perflutren Lipid Microsphere Injectable Suspension, Lantheus Medical Imaging, North Billerica, MA) was approved by the US Food and Drug Administration in 2001 for “opacification of the left ventricular border in patients with technically difficult echocardiograms”. Since then, product labeling has been substantially revised on three occasions, initially due to safety concerns, and more recently to reflect a large body of literature which supports the excellent risk–benefit profile of this agent. This article describes in detail the substantive modifications of the product labeling for DEFINITY since 2001, and the associated supportive scientific data and public regulatory meetings.
美国DEFINITY®产品标签变更历史
以前未被满足的临床需求:在美国,至少有10 - 15%的超声心动图在技术上是困难的,通常是因为患者相关的因素,包括肺部疾病和肥胖。这类考试通常是通过UCA的管理来挽救的。这可以防止下游测试,降低医疗保健成本,并导致更及时和准确的诊断。22在产品批准时,DEFINITY在两个患者亚群中禁用:已知对八氟丙烷(全氟烷,DEFINITY微泡中的成分气体)过敏的患者和已知有心脏分流的患者。此外,产品标签明确禁止动脉内注射和既往对全氟仑过敏反应的患者使用。分流术患者的禁忌症和禁止动脉内注射与理论上对全身栓塞可能性的担忧有关。尽管DEFINITY微泡的直径范围从1.1 μ m到3.3 μ m,但这些微泡中约有2%为> - 10 μ m,最大直径为20 μ m。尽管在正常情况下,这一小部分> - 10 μ m微泡被肺微血管过滤,较大的微泡可以进入心内分流(或直接动脉内注射)患者的体循环,Abstract DEFINITY®(全氟化脂质微球注射混悬液,Lantheus Medical Imaging, North Billerica, MA)于2001年获得美国食品和药物管理局批准,用于“超声心动图技术困难患者的左心室边界混浊”。从那时起,产品标签进行了三次实质性修订,最初是出于安全考虑,最近是为了反映大量文献,这些文献支持该制剂的良好风险-收益概况。本文详细描述了自2001年以来对DEFINITY产品标签的实质性修改,以及相关的支持性科学数据和公共监管会议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信